#United States #San Diego #Neurocrine Biosciences #INGREZZA #Tardive Dyskinesia

Neurocrine Biosciences' Latest Publication on Tardive Dyskinesia

Neurocrine Biosciences, Inc. has recently released an important peer-reviewed study in The Journal of Clinical Psychiatry, revealing significant insights into the treatment of tardive dyskinesia (TD) using the Tardive Dyskinesia Impact Scale (TDIS™). This publication highlights how TDIS aids in capturing the complexity of patients’ experiences and improvements as they undergo treatment with INGREZZA® (valbenazine) capsules.

Understanding Tardive Dyskinesia and Its Impact

Tardive dyskinesia is a movement disorder marked by involuntary, erratic movements that can impact various body parts, including the face and torso. It often arises as a side effect of long-term use of certain antipsychotic medications. The impact of TD goes beyond physical limitations, affecting social interactions and emotional well-being, which underscores the need for a comprehensive measurement tool like TDIS.

The Tardive Dyskinesia Impact Scale (TDIS™)

Developed in collaboration with neurology and psychiatry professionals, the TDIS is the first patient-reported outcome measure specifically validated for individuals with TD. This unique scale focuses not only on physical impairments but also on socio-emotional distress caused by involuntary movements. By assessing these multifaceted aspects, TDIS provides a holistic view of how TD affects daily life.

Clinical evidence suggests that the visible severity of tardive dyskinesia may not adequately reflect the burden experienced by patients. As Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, indicates, understanding the patient's perspective is essential for evaluating treatment effectiveness. This study reinforces the clinical value of integrating patient-reported outcomes to inform treatment decisions.

Defining Clinically Meaningful Improvement

One of the significant findings of this research is the establishment of a minimal clinically important difference of four points on the TDIS total score. This benchmark helps define what constitutes a meaningful improvement in a patient’s condition from both clinician and patient perspectives. In clinical studies such as KINECT® 3 and KINECT® 4, TDIS effectively captured improvements across various dimensions of life affected by TD, aligning with clinician assessments of movement severity.

The KINECT-PRO™ study further corroborates these findings, demonstrating that patients treated with INGREZZA reported substantial enhancements in their physical, social, and emotional functioning. TDIS provides a platform for patients to express how their symptoms influence day-to-day activities, allowing providers to gauge the comprehensive impact of treatment.

Implications for Patients and Clinicians

These insights are pivotal not only for understanding treatment responses but also for informing future clinical practices. With the integration of TDIS into treatment frameworks, clinicians can better navigate the complexities of TD management, tailoring intervention strategies aligned with patients’ needs.

In conclusion, Neurocrine Biosciences' commitment to advancing our understanding of tardive dyskinesia through thorough research is a crucial step in enhancing patient care. By focusing on both clinical and patient-reported outcomes, this publication adds a valuable dimension to the ongoing dialogue surrounding TD treatment and management. The detailed findings can be accessed in the complete manuscript titled Measuring What Matters: Further Validation for the Tardive Dyskinesia Impact Scale available in the journal.

About Neurocrine Biosciences

Neurocrine Biosciences is dedicated to developing innovative treatments for neurological and psychiatric disorders. As a leader in the biopharmaceutical field, the company continues to focus on addressing unmet medical needs through its diverse portfolio and robust pipeline of clinical candidates. This commitment is exemplified by their rigorous study designs and ongoing research efforts that prioritize patient perspectives in treatment outcomes.